Flucytosine (5-fluorocytosine) is an antimetabolite agent, classified as a systemic antifungal. It was first made in 1957 and FDA approved in 1971 for the treatment of severe candida and cryptococcus infections. Once administered, flucytosine's pharmacologic effect only takes place in the presence of fungal cells, and the action does not act on mammalian cells. The use of flucytosine as monotherapy is not advised due to the high risk of drug resistance to its use individually. It may be used without the addition of a second medication when treating non-systemic, non-life threatening conditions such as candida infections that affect the lower urinary tract and vagina. The recommended use is alongside another antifungal medication. A standard sequence of flucytosine use is with amphotericin B, which serves a synergistic effect when used together for systemic infections. The combination therapy can treat cryptococcosis meningitis, and candidosis causing endocarditis, meningitis, endophthalmitis, peritonitis, cystitis, and systemic infection. The use of this medication is done on a case by case basis as this drug is heavily reliant on an individual's kidney function. The drug does not undergo metabolism within the human body, and by 24 hours, 85 to 95% of flucytosine is excreted in the urine without changing from its original form.
FDA Approved Use
Clinicians use flucytosine in combination with amphotericin B for invasive cryptococcal (meningitis) and candida infections.
Flucytosine (5-FC) action takes effect when it comes in contact with the fungus, and is taken up by an enzyme known as cytosine permease. Once the drug has entered the fungus, it is then converted to its active form 5-fluorouracil(5-FU), by the enzyme cytosine deaminase within the cell. 5-fluorouracil incorporates itself into the RNA strand by competing with uracil, disrupting the RNA synthesis, and impairing protein synthesis within the fungus. 5-fluorouracil also further inhibits DNA synthesis by its conversion into fluoro-deoxyuridylic acid and inhibiting thymidylate synthase, which causes DNA damage within fungal cells. The enzyme cytosine deaminase is not present in mammalian cells, which is the understanding of its inactivity in bacteria and human cells.
The medication can be started on an oral dosage of 50 mg to 150 mg/kg/day every six hours. Once orally administered, the medication is well absorbed in the gastrointestinal tract with a 75 to 90% bioavailability, and is eliminated by glomerular filtration of the kidneys and excreted in the urine.
Flucytosine is available as a solution and is available in the following dosages:
Flucytosine administered by infusion should maintain concentrations of 50 mg/L.
The FDA has not approved flucytosine for intrathecal administration.
There are also reports of more severe hematologic adverse effects such as bone marrow suppression, pancytopenia, aplastic anemia, and agranulocytosis. Inflammatory bowel disease such as ulcerative colitis and perforation of the bowel are among the more severe but rare gastrointestinal adverse effects of flucytosine.
Flucytosine is contraindicated in patients who have a hypersensitivity to the medication. During pregnancy, flucytosine use is not indicated during the first trimester as anatomic irregularities have appeared during aborted pregnancies. There have been no evidenced reports of toxicity during the second and third trimesters. It should only be administered to the mother once the benefits outweigh the uncertainties, as the drug can readily cross the placenta. The FDA has labeled flucytosine as risk category C during pregnancy. Breastfeeding is also not recommended during flucytosine use.
It is vital to monitor the liver enzymes, CBC, and kidney functions regularly for patients taking flucytosine. The serum drug concentrations require thorough monitoring for patients receiving high dosages or extended durations of the treatment. The drug concentration is considered non-toxic and adequate at a level below 100 mg/L. With levels above 100 mg/L, toxicity may occur. The onset of action and half-life of this medication is dependent on the individual and their kidney function. The half-life of flucytosine in healthy individuals is 2 to 5 hours. It can be notably lengthened in subjects who have an insufficient organ function. The onset of peak levels is usually 2 hours in a healthy person with normal kidney function. In individuals with compromised renal function, peak onset can be 4 to 5 hours due to decreased elimination of the drug.
Flucytosine toxicity can present with hepatitis and gastrointestinal symptoms such as diarrhea, nausea, and vomiting. More severe symptoms, such as leukopenia and thrombocytopenia, can also develop. The adverse effects and toxicity of flucytosine are concentration-dependent and can be managed by decreasing the dosage or by discontinuation of the medication if complications do arise. In the event severe toxicity does pursue, the drug is manageable through hemodialysis, or peritoneal dialysis, as 97% of the drug is excreted through glomerular filtration of the kidneys.
Flucytosine (5-fluorocytosine) is an FDA-approved medication indicated for the treatment of severe candida and cryptococcus infections. Administering care to patients prescribed flucytosine prompts excellent interaction between the patient and interprofessional healthcare providers. These providers include a primary care physician, an infectious disease specialist, a nurse, and a pharmacist. The primary care physicians and infectious disease doctor necessitate exceptional patient rapport, so the patient thoroughly comprehends the significance of medication compliance and is educated on the treatment of flucytosine for the illness and its complications. The patients should receive routine checkups to monitor if the flucytosine is in an optimal range, and the patient is not experiencing any toxicities and harm to the liver, kidneys, or bone marrow. The primary care and specialist should be up to date with the latest guidelines of management with flucytosine, its implications, and adverse effects. Recommendations are not to use flucytosine as monotherapy due to likely drug resistance, and it's frequent use with nephrotoxic medication amphotericin B. If toxicity and organ damage does pursue, it is vital to dialyze the patient as 85 to 95% of the medication is excreted through the urine. Joint decision making between the interprofessional team is essential to improve patient-centered care and reach the coveted outcome.
|||Flucytosine . 2012 [PubMed PMID: 31643936]|
|||Bellmann R,Smuszkiewicz P, Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017 Dec [PubMed PMID: 28702763]|
|||Fisher JF,Sobel JD,Kauffman CA,Newman CA, Candida urinary tract infections--treatment. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 May [PubMed PMID: 21498839]|
|||Day JN,Chau TTH,Wolbers M,Mai PP,Dung NT,Mai NH,Phu NH,Nghia HD,Phong ND,Thai CQ,Thai LH,Chuong LV,Sinh DX,Duong VA,Hoang TN,Diep PT,Campbell JI,Sieu TPM,Baker SG,Chau NVV,Hien TT,Lalloo DG,Farrar JJ, Combination antifungal therapy for cryptococcal meningitis. The New England journal of medicine. 2013 Apr 4 [PubMed PMID: 23550668]|
|||Spec A,Powderly WG, Cryptococcal meningitis in AIDS. Handbook of clinical neurology. 2018 [PubMed PMID: 29604972]|
|||Houšť J,Spížek J,Havlíček V, Antifungal Drugs. Metabolites. 2020 Mar 12 [PubMed PMID: 32178468]|
|||Antonello VS,Appel da Silva MC,Cambruzzi E,Kliemann DA,Santos BR,Queiroz-Telles F, Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Revista do Instituto de Medicina Tropical de Sao Paulo. 2010 Nov-Dec [PubMed PMID: 21225217]|
|||Edlind TD,Katiyar SK, Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrobial agents and chemotherapy. 2010 Nov [PubMed PMID: 20823283]|
|||Kunka ME,Cady EA,Woo HC,Thompson Bastin ML, Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy. Case reports in critical care. 2015 [PubMed PMID: 26246919]|
|||Sakkas A,Zarogoulidis P,Domvri K,Hohenforst-Schmidt W,Bougiouklis D,Kakolyris S,Zarampoukas T,Kioumis I,Pitsiou G,Huang H,Li Q,Meditskou S,Tsiouda T,Pezirkianidis N,Zarogoulidis K, Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines. Journal of Cancer. 2014; [PubMed PMID: 24799955]|
|||Kyriakidis I,Tragiannidis A,Munchen S,Groll AH, Clinical hepatotoxicity associated with antifungal agents. Expert opinion on drug safety. 2017 Feb [PubMed PMID: 27927037]|
|||Folk A,Balta C,Herman H,Ivan A,Boldura OM,Paiusan L,Ardelean A,Hermenean A, Flucytosine and Amphotericin B Coadministration Induces Dose-Related Renal Injury. Dose-response : a publication of International Hormesis Society. 2017 Apr-Jun [PubMed PMID: 28620270]|
|||Sohail MA,Ikram U, Flucytosine-induced colitis. BMJ case reports. 2014 Apr 28 [PubMed PMID: 24777084]|
|||Pilmis B,Jullien V,Sobel J,Lecuit M,Lortholary O,Charlier C, Antifungal drugs during pregnancy: an updated review. The Journal of antimicrobial chemotherapy. 2015 Jan; [PubMed PMID: 25204341]|
|||[PubMed PMID: 27906037]|